Beijing, China
MoleculeMind, founded in 2022, is making strides in the Biotechnology and Pharmaceutical industries with its AI-Driven Protein Discovery and Design. The company specializes in revolutionizing protein design and optimization through its flagship platform, MoleculeOS. By leveraging cutting-edge AI algorithms, MoleculeMind empowers professionals across various fields, including chemistry, materials science, synthetic biology, and agriculture, to efficiently identify and generate a wide range of proteins such as peptides, antibodies, enzymes, and small proteins.
The platform's broad application capabilities are transforming the landscape of protein-related R&D, marking a significant advancement in innovation and commercial progress for the industries it serves. In its recent financing round, MoleculeMind secured a CNY200.00M Series A investment on 01 September 2024, with backing from notable investors such as Shenzhen Capital Group, Shangjiu Investment, Sense Capital, and Guangzhou Xie Nuo Investment Group. This injection of capital underscores confidence in the company's vision and potential for significant market impact.
